Department of Defense Psychological Health and Traumatic Brain Injury Research Program (PHTBIRP)
The Federal Interagency Traumatic Brain Injury Research (FITBIR) data identifies actionable insights for the diagnosis, management, and treatment of traumatic brain injury.Prevention Research to Reduce Sexual Assault and/or Understand Adjustment Disorders Investigator-Initiated Focused Research Award (PSAAD-IIFRA) – supports research focused on (1) development/adaptation efforts to reduce the occurrence of sexual assault and/or harassment, (2) understanding the diagnosis, assessment, and screening of adjustment disorders resulting from sexual assault and/or stressors that precipitate adjustment disorders. Human subject research is permitted, but award may not be used to conduct clinical trials. Preclinical animal research is not permitted. Max funding $750K (direct/indirect costs) for 3 yrs.Clinical Research Award (CTRR-CRA) – supports applied/translational research to advance knowledge/products for rehabilitation and function restoration after traumatic brain injury. Max funding $2 million (direct/indirect costs) for 3 years. CTRR – Clinical Trial Award (CTRR-CTA) – supports clinical trials to validate existing complex mild TBI (mTBI) rehabilitation interventions and practice patterns; Clinical trials must measure intervention effects and effectiveness of standard-of-care practices in remediating post mTBI sequelae across the spectrum of functional vulnerabilities. Max funding $4 million (direct/indirect costs) for 3 years.

___________________
Department of Defense Melanoma Research Program
The DoD Melanoma Research Program (MRP) supports innovative, high-impact melanoma research (e.g., precursor lesions, melanomagenesis, host factors, tumor microenvironment/evolution; therapeutic prevention: residual disease; rare melanomas).
Idea Award – $300,000 (direct/indirect costs) for 3 yrs; Team Science Awards (2-3 investigators must partner in a multidisciplinary research study), $700,000 (direct/indirect) costs for 3 yrs; and Translational Research Award – studies with existing biobanks, biorepositories, ongoing/completed clinical trials on translational melanomas. DoD/VA participation encouraged, preliminary data required, and new clinical trials not allowed. Max $600,000 (direct/indirect costs) for 3 yrs.
Concept Award – October 2, 2019 (Letter of Intent); October 23, 2019 (Full application)
For the exploration of highly innovative, untested, melanoma concepts. Preliminary data strongly discouraged and clinical trials are not allowed. $75,000 in direct costs (indirects negotiated) for 1 yr.

___________________
Department of Defense Gulf War Illness Research Program
The GWIRP supports research in Gulf War Illness pathobiology, diagnosis, and treatment.

Idea Award – Max funding $150,000 for direct/indirect costs. Max funding of $170,000 (direct/indirect costs) Biorepository Contribution Option; Max period 2 yrs. Clinical Evaluation Award – Max funding $1,000,000 (direct/indirect costs); Max funding $1,020,000 (direct/indirect costs) with Biorepository Contribution. Max funding $1,200,000 (direct/indirect costs) with Clinical Consortium Collaboration for 3 yrs. Therapeutic/Biomarker Trial Award – Max funding $5,000,000 (direct/indirect costs); Max funding $5,020,000 (direct/indirect costs) for Biorepository Contribution; Max funding $5,500,000 (direct/indirect costs) Clinical Consortium Collaboration for 4 yrs. Patient-Provider and Health Communications Award – Max funding $700,000 (direct/indirect costs) for 3 yrs. New Investigator Award – 3 eligibility categories: Transitioning Postdoc; Postdoc (3 yrs of postdoc training); Early-Career Investigator (5 yrs since last training position); New GWI researcher (Established PI with less than $300,000 in federally funded, non-mentored GWI research). GWI researchers collaborations strongly encouraged. Preliminary data not required; Clinical trials not allowed. Max funding $500,000(direct/indirect costs); Max funding $520,000 (direct/indirect costs) with Biorepository Contribution. Research Advancement Award – Max funding $700,000 for direct/indirect costs. Max funding $720,000 (direct/indirect costs) Biorepository Contribution for 3 yrs.

___________________
DEPSCoR: Defense Established Programs to Stimulate Competitive Research
U.S. Army YIP is a rolling acceptance program with no fixed submission date.
The Army Research Office (ARO), Air Force Office of Scientific Research (AFOSR), and Office of Naval Research (ONR) build facility capacity/increase research infrastructure. DEPSCoR augments existing programs in DEPSCoR-eligible states/territories. Specifically: Young Investigator Program (YIP) and the Defense University Research Instrumentation Program (DURIP):  (1) Helps higher education develop science and engineering (S&E) research relevant to DoD mission; (2) Increase university researchers doing S&E research in eligible states/territories; and (3) Increase long-term growth in eligible states/territories that receive federal S&E funding.

___________________
Department of Defense Vision Research Program
The VRP supports military vision research in: Eye injury or visual dysfunction; Blast, blunt, thermal, or chemical trauma; Trauma caused by directed energy weapons; Diagnosis/treatment of eye injuries in austere environment. Investigator-Initiated Research Award – Level I Max funding $260,000 (direct/indirect costs) for 2 yrs. Level II Max funding $500,000 (direct/indirect costs) for 3 years. Translational Research Award – Max funding of $750,000 (direct/indirect costs) for 3 yrs. Focused Translational Team Science Award – Lead PI is required to have minimum 20% effort. Applications must include 3-5 five research projects. Max funding $5,000,000 (direct/indirect costs) for 4 yrs.

___________________

Department of Defense Kidney Cancer Research Program (KCRP)
The KCRP Concept Award supports highly innovative, untested, novel concepts in kidney cancer.
Concept Award – Max funding of $75,000 for direct/indirect costs for 1 yr. Clinical trials not allowed. Preliminary data not allowed. Idea Development Award – Preliminary data required. Clinical trials not allowed. Maximum funding of $400,000 in direct/indirect costs for 2 yrs. Translational Research Partnership Award -Max funding of $600,000 for direct/indirect costs for 3 yrs. Supports partnerships between clinicians/scientists that accelerate kidney cancer clinical applications; Supports translational correlative studies; Preliminary data required; Clinical trials not allowed.

_____________________
Department of Defense Clinical and Rehabilitative Medicine Research Program
The (JPC-8/CRMRP) supports the development of regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damage due to traumatic injury through collaborative partnerships and synergistic projects. All projects  required to address peripheral nerve and/or skeletal muscle regeneration.

_______________________
Department of Defense Prostate Cancer Research Program (PCRP)
The PCRP develops treatments to improve prostate cancer outcomes, reduce prostate cancer in African Americans, Veterans, and high-risk populations, define prostate cancer biology, and improve survivors quality of life.

Idea Award – Max funding $750,000 for direct/indirect costs. New Investigators – Max funding $600,000 (direct/indirect costs) for 3 yrs. Early Investigator Award – Max funding $200,000 (direct/indirect costs) for 2 years. Physician Research Award – Max funding $750,000 (direct/indirect costs) for 4 years. Clinical Trial Award – Early-phase clinical trials (e.g., Phase 0, Phase I, pilot Phase II) to test interventions. Max funding $2,000,000 (direct/indirect costs) for 4 yrs. Health Disparity Research Award – Max funding $750,000 (direct/indirect costs); New Investigators – Max funding $600,000 (direct/indirect costs) for 3 yrs. Synergistic Population and Data Science Award – Max funding $1,500,000 (direct/indirect costs) for 4 yrs. Translational Science Award – Max funding $750,000 (direct/indirect costs) for 3 yrs.

__________________
Department of Defense Epilepsy Research Program (ERP) and Idea Development Award
The ERP FY19 Focus Areas are in Basic Research (e.g., biomarkers, therapeutic targets, early detection); Epidemiology (e.g., risk factors); and Longitudinal Studies (e.g., seizure frequency/severity, anatomy/pathology, injury type, depression, sleep disorders). Max funding of $300,000 – Level I for direct/indirect costs for 3 yrs. and $500,000 – Level II for 3 yrs.

___________________
Department of Defense Peer Reviewed Breast Cancer Research Program (BCRP)
The BCRP FY19 Focus Areas are Level I – Early stage, high risk/high-reward research; Level II – Preclinical research supported by substantial preliminary/published data with clinical translation partnering; and Level II – Population science and prevention studies. Level I – Max funding of $450,000 ($750,000 with partnering) for direct/indirect costs for 3 yrs. Level II – Max funding of $1 million ($1.5 million with partnering) for direct/indirect costs for 3 yrs. Level II Population science and prevention studies – Max funding of $1.5 million ($2 million with partnering) for direct/indirect costs for 4 yrs.

___________________
Department of Defense Lung Cancer Research Program (LCRP)
The LCRP seeks to identify innovative strategies for the early detection of lung cancer; understand the molecular mechanisms, prevention, treatment, and recurrence of lung cancer.

Concept Award – Max funding $100,000 for direct/indirect costs. for 1 yr. Clinical trials not allowed. Relevance to Military Health strongly encouraged. Career Development Award – Max funding $250,000 (direct/indirect costs) for 2 yrs.

___________________

Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP)
PRORP’s Applied Research Award seeks research in the following FY19 focus areas: 1) Compartment Syndrome Models, Limb Stabilization and Protection; 2) Rapid Limb Stabilization/Wound Protectants; 3) Retention on Duty Strategies; 4) Skin-implant Interface; 5) Translation of Early Findings to Clinical Trials/practice; and 6) Tissue Regeneration Therapeutics. Max funding of $750,000 for total costs (direct/indirect costs) for 3 yrs.
Clinical Trial Award Same focus areas/deadline. Max funding of $2.5 million – Level I (direct/indirect costs) for 4 yrs. and max funding of $3M (direct/indirect) for 4 yrs.
Clinical Translational Research Award Same focus areas/deadline. Max funding of $2M (direct/indirect costs) for 4 yrs.

____________________
Department of Defense Peer Reviewed Alzheimer’s Research Program
The DoD Peer Reviewed Alzheimer’s Research Program (PRARP) supports research on long-term consequences of traumatic brain injury for Alzheimer’s disease/dementias via 5 award mechanisms – Convergence Science Research Award, Innovation in Care and Support Award, Research Partnership Award (RPA), Accelerating Diagnostics for Traumatic Brain Injury Research Award (ADTBI) and Leveraging Approaches for Innovation in Care and Support Award (LEAP-InCASA).  Topical areas include: Paucity of Research Resources; Paucity of Clinical Studies; Diagnostics/Prognostics; Epidemiology; Quality of Life; and Family/Care Support. PRARP focus areas include: mechanisms of pathogenesis, biomarkers, epidemiology, novel target identification, and bioinformatics. Max funding of Level I – $225,000 (direct/indirect) costs for 3 yrs.  Level II – Max funding of $500,000 (direct/indirect costs) for 3 yrs. RPA – Max funding of $1.3 Million for 3 yrs.  ADTBI – Max funding of $2.8 million for 4 yrs. LEAP-InCASA – Max funding of $2.8 million for 4 yrs.

___________________
Dept. of Defense Amyotrophic Lateral Sclerosis Research Program
The FY20 ALSRP supports innovative/impactful research on new ALS treatments.
Therapeutic Development Award – Pre-application required; full application by invitation only; Supports preclinical secondary validation and IND-enabling studies of ALS therapeutics and efficacy in one ALS-relevant model system with a lead molecule/class of compounds; and biomarker development. Max funding of $1,000,000 (direct/indirect) costs for 3 yrs.
Therapeutic Idea Award – Pre-application required; full application by invitation only; preclinical therapeutic development; preliminary data not required. Early Career Investigators encouraged to apply. Applications on biomarkers will qualify for more funding. Max funding of $500,000 (direct/indirect) costs or $600,000 (direct/indirect) costs for Therapeutic Relevant Biomarker option for 2 yrs.
Clinical Development Award – Pre-application required; full application submission by invitation only. Supports leveraging of human-based ALS resources via clinical research; Early Career Investigators/Physician Scientists encouraged to apply.  Supports using human subject-based resources to better define subtypes, predict therapeutic response, or assess prognosis; Correlating clinical trial-related biosamples, imaging, or epidemiological data with clinical outcomes; and studies to evaluate optimizing current ALS clinical care. Max funding of $300,000 (direct/indirect) costs for 2 yrs.
___________________
Department of Defense Neurofibromatosis Research Program (NFRP)
NFRP supports innovative, high-impact NF research and seeks to address: Biomarker discovery, utility, development, and validation; Non-tumor manifestations (pain, cognitive manifestations, sleep, heterogeneity of NF-related tumors; disease/treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics); preclinical efficacy studies; targets, drug discovery; nutritional, environmental; and health services research.

Clinical Trial Award – must support a clinical trial and not used for preclinical studies; Scientific rationale/prelim data required for Phase I, II clinical trials. Max funding of $800,000 for (direct/indirect costs); Max funding $1M (direct/indirect costs) with collaborator for 4 yrs.
Exploration – Hypothesis Development Award – Prelim/published data encouraged, not required; Clinical trials allowed; Max $100,000 (direct/indirect costs) for 2 yrs.
Investigator-Initiated Research Award – Investigators must commit at least a 10% effort/budget period; Prelim/published data required; Clinical trials allowed; Max funding  $525,000 (direct/indirect costs); Max $575,000 (direct/indirect costs) with collaborator; Max funding $625,000 (direct/indirect costs) for 3 yrs.
New Investigator Award – NF experience is allowed, but not required; Prelim/or published data is required; Clinical trials not allowed; Max $450,000 (direct/indirect costs) for 3 yrs.
Early Investigator Research Award – Postdoctoral Ph.D. or M.D. PIs; Supports research on NF for PIs in early career stages; PIs must have an experienced NF mentor; Max $200,000 for (direct/indirect costs) for 2 yrs.
Synergistic Idea Award – Supports partnerships of 2-3  investigators to address a NF problem (may be high risk with potential for high impact); Must show synergism (i.e., leveraging disciplines, expertise or critical resources) to advance the project outcome rapidly/efficiently that could not be accomplished independently. Prelim/published data required; Synergy, Research Strategy, Personnel, and Impact most important review criteria; Clinical trials not allowed; Max $2M (direct/indirect costs) for 3 yrs.

_________________